ClassID:

20995

A61K38/2292 - CPC Classification

Classification description:

Medicinal preparations containing peptides; Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans; Hormones Thymosin; Related peptides

Recent Application in this class:
#1
20260115258
2026-04-30

PEPTIDE COMPOSITIONS FOR TREATING HAIR LOSS

#2
20250281531
2025-09-11

METHODS AND COMPOSITIONS FOR DETOXIFICATION OF CHRONIC EXPOSURE TO TOXINS

#3
20250127769
2025-04-24

ANTI-TUMOR PHARMACEUTICAL COMPOSITION BASED ON IMMUNE CHECKPOINT BLOCKADE AND USE THEREOF

#4
20240091314
2024-03-21

USE OF THYMOSIN ALPHA FOR THE TREATMENT OF SEPSIS

#5
20240058421
2024-02-22

ENHANCING CHEMOTHERAPY IN MEDULLOBLASTOMA AND GLIOBLASTOMA WITH HIGH BASAL p53 LEVELS

#6
20230285513
2023-09-14

TREATMENT OF CANCER WITH IMMUNE STIMULATORS

#7
20230285512
2023-09-14

COMPOSITIONS AND METHODS FOR TREATING MYOCARDIAL INFARCTION AND ISCHEMIA

#8
20230190878
2023-06-22

BETA THYMOSIN PEPTIDES FOR TREATING VIRAL INFECTIONS

#9
20230173031
2023-06-08

Thymosin alpha 1 for use in treatment of cystic fibrosis

#10
20230050258
2023-02-16

IMMUNOTHERAPEUTIC TREATMENT OF CANCER

#11
20230025377
2023-01-26

COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING PRURITUS

#12
20220257721
2022-08-18

PHARMACEUTICAL COMPOSITION CONTAINING GLY-THYMOSIN BETA-4 (GLY-TB4) FOR TREATMENT OF DRY EYE

#13
20220241379
2022-08-04

Enhancing chemotherapy in medulloblastoma and glioblastoma with high basal p53 levels

#14
20220241378
2022-08-04

COMPOSITIONS AND METHODS FOR TREATMENT OF CHRONIC GRANULOMATOUS DISEASE

#15
20220008380
2022-01-13

METHODS OF TREATING COVID-19 PATHOGENESIS

#16
20210330706
2021-10-28

Children Blood Transfusion and Thymus Hormonal Therapy as Antiviral and Antibacterial Compounds

#17
20210290823
2021-09-23

Muscle cell patches and uses therefor

#18
20210244797
2021-08-12

Enhancing chemotherapy in medulloblastoma and glioblastoma with high basal p53 levels

#19
20210213103
2021-07-15

METHODS OF TREATING DRY EYE SYNDROME

#20
20210106656
2021-04-15

USE OF THYMOSIN ALPHA FOR THE TREATMENT OF SEPSIS

#21
20210077585
2021-03-18

METHOD OF TREATMENT OF IMMUNE CHECKPOINT INHIBITOR-RELATED IMMUNE ADVERSE EFFECTS

#22
20200353052
2020-11-12

COMPOSITION FOR PROMOTING GOBLET CELL PROLIFERATION OR MUCIN SECRETION COMPRISING THYMOSIN BETA 4 OR DERIVATIVE THEREOF AS ACTIVE INGREDIENT

#23
20200352851
2020-11-12

METHOD OF TREATING AN EYE DISORDER BY INHIBITING OR DISRUPTING BACTERIAL BIOFILM FORMATION

#24
20200319209
2020-10-08

Modulation of gene expression in a human bioreactor

#25
20200289618
2020-09-17

Treatment of cancer with alpha thymosin peptide and PD-1 inhibitors

#26
20200239858
2020-07-30

RECOMBINANT VECTORS

#27
20200237904
2020-07-30

Methods and Compositions Useful for Treating Cancer

#28
20200171206
2020-06-04

Compositions and methods for improving cardiac function

#29
20200023039
2020-01-23

Thymosin alpha 1 for use in treatment of cystic fibrosis

#30
20190240294
2019-08-08

Methods of treating dry eye syndrome

#31
20190231881
2019-08-01

Pharmaceutical compositions with enhanced stability

#32
20190142999
2019-05-16

Muscle cell patches and uses therefor

#33
20190134142
2019-05-09

Multi-factor hair growth formulation

#34
20190091494
2019-03-28

PEPTIDES FOR HAIR GROWTH

#35
20190091142
2019-03-28

Method of treating an eye disorder by inhibiting or disrupting bacterial biofilm formation

#36
20180280479
2018-10-04

Stabilized external preparation comprising thymosin beta 4 as an active ingredient

#37
20180236036
2018-08-23

USE OF THYMOSIN ALPHA FOR THE TREATMENT OF SEPSIS

#38
20180228729
2018-08-16

Method for preparing ophthalmic preparation containing thymosin beta-4

#39
20180161399
2018-06-14

TREATMENT OF CANCER WITH IMMUNE STIMULATORS

#40
20180087035
2018-03-29

Recombinant vectors

#41
20180050108
2018-02-22

Methods of making pharmaceutical compositions with enhanced stability

#42
20180036381
2018-02-08

Thymosin alpha 1 for use in treatment of cystic fibrosis

#43
20180028619
2018-02-01

LKKTET and/or LKKTNT peptide compositions which are lyophilized or in a form capable of being lyophilized

#44
20170333531
2017-11-23

Composition containing thymosin beta 4, and pharmaceutical formulation comprising same

#45
20170326207
2017-11-16

Thymosin Beta 4 Promotes Wound Repair

#46
20170224740
2017-08-10

Methods for treating traumatic brain injury with amnion-derived cellular cytokine solution (ACCS) or amnion-derived multipotent progenitor (AMP) cells

#47
20170128540
2017-05-11

EYE DROP FORMULATION

#48
20170087203
2017-03-30

Wound healing using topical systems and methods

#49
20170049857
2017-02-23

Pharmaceutical composition for treating or preventing corneal wound comprising thymosin β4 and citric acid

#50
20160287673
2016-10-06

COMPOSITIONS AND METHODS FOR TREATING CORNEAL EPITHELIAL WOUND

#51
20160263143
2016-09-15

Methods for the treatment of hepatitis B and hepatitis D infections

#52
20160263017
2016-09-15

Nuclear localization of GLP-1 stimulates myocardial regeneration and reverses heart failure

#53
20160250384
2016-09-01

Muscle cell patches and uses therefor

#54
20160201055
2016-07-14

Methods, systems, and compositions relating to miRNA-146a

#55
20160193301
2016-07-07

Eye drop formulation

#56
20160158370
2016-06-09

Wound healing using topical systems and methods

#57
20160106812
2016-04-21

Treatment of cancer with immune stimulators

#58
20160053232
2016-02-25

Recombinant vectors

#59
20150224175
2015-08-13

Methods, systems, and compositions for promoting recovery of peripheral neuropathy

#60
20150150771
2015-06-04

Composition and method for an intradermal hair growth solution

#61
20150037281
2015-02-05

VARIANTS OF PROTHYMOSIN ALPHA AND METHODS OF USING SAME

#62
20150031617
2015-01-29

USE OF THYMOSIN ALPHA FOR TREATMENT OF PURULENT RHINOSINUSITIS

#63
20150024994
2015-01-22

USE OF THYMOSIN ALPHA FOR THE TREATMENT OF SEPSIS

#64
20140369963
2014-12-18

Methods for the treatment of hepatitis B and hepatitis D infections

#65
20140369962
2014-12-18

Methods for the treatment of hepatitis B and hepatitis D infections

#66
20140271802
2014-09-18

Wound healing using topical systems and methods

#67
20140213506
2014-07-31

THYMOSIN ALPHA PEPTIDE FOR PREVENTING, REDUCING THE SEVERITY OF, AND TREATING INFECTION

#68
20140065102
2014-03-06

Methods for the treatment of hepatitis B and hepatitis D infections

#69
20140017193
2014-01-16

Methods for treating nervous system injury and disease

#70
20130309201
2013-11-21

Oligonucleotide chelate complex—polypeptide compositions and methods

#71
20130296223
2013-11-07

USE OF THYMOSIN ALPHA FOR THE TREATMENT OF SEPSIS

#72
20130130986
2013-05-23

CANCER TREATMENT WITH RECOMBINANT VECTOR

#73
20130090289
2013-04-11

Method of treatment of type 2 diabetes

#74
20130078218
2013-03-28

HEPATITIS C THERAPIES

#75
20120295840
2012-11-22

Treatment of infections with alpha thymosin peptides

#76
20120230941
2012-09-13

Methods for treating nervous system injury and disease

#77
20120213735
2012-08-23

THERAPEUTIC FUROPYRIMIDINES AND THIENOPYRIMIDINES

#78
20120208995
2012-08-16

Macrocyclic inhibitors of hepatitis C virus replication

#79
20120165259
2012-06-28

Agent for ameliorating blood-brain barrier disorders

#80
20120114604
2012-05-10

Combinations for HCV Treatment

#81
20120071411
2012-03-22

LKKTET and/or LKKTNT peptide compositions which are lyophilized or in a form capable of being lyophilized

#82
20120065132
2012-03-15

Method of treating or preventing tissue deterioration, injury or damage due to congestive heart failure

#83
20120021992
2012-01-26

Methods for improving neurological outcome after neural injury and neurodegenerative disease

#84
20110318401
2011-12-29

TREATMENT OF LEG ULCERS USING PLACENTA DERIVED COLLAGEN BIOFABRIC

#85
20110287020
2011-11-24

Recombinant vectors

#86
20110281802
2011-11-17

COMPOSITION FOR TREATMENT AND PREVENTION OF HAIR LOSS AND PREMATURE GRAYING OF HAIR

#87
20110165121
2011-07-07

USE OF PEGYLATED TYPE III INTERFERONS FOR THE TREATMENT OF HEPATITIS C

#88
20110144020
2011-06-16

TREATMENT OF INFECTIONS AND OTHER DISORDERS

#89
20110124550
2011-05-26

THYMOSIN BETA 4 PROMOTES WOUND REPAIR

#90
20110044941
2011-02-24

IMMUNOTHERAPY FOR REVERSING IMMUNE SUPPRESSION

#91
20110020449
2011-01-27

METHODS OF TREATING DISORDERS OF THE EYE AND SURROUNDING TISSUE WITH THYMOSIN BETA 4 (TB4), ANALOGUES, ISOFORMS AND OTHER DERIVATIVES

#92
20100330093
2010-12-30

TREATMENT OF MELANOMA WITH ALPHA THYMOSIN PEPTIDES IN COMBINATION WITH ANTIBODIES AGAINST CYTOTOXIC T LYMPHOCYTE-ASSOCIATED ANTIGEN 4 (CTLA4)

#93
20100317583
2010-12-16

TREATMENT OF MELANOMA WITH ALPHA THYMOSIN PEPTIDES IN COMBINATION WITH AN ANTINEOPLASTIC HEAT SHOCK APOPTOSIS ACTIVATOR (HSAA)

#94
20100311656
2010-12-09

TREATMENT OR PREVENTION OF RESPIRATORY VIRAL INFECTIONS WITH ALPHA THYMOSIN PEPTIDES

#95
20100285060
2010-11-11

Alpha thymosin peptides as vaccine enhancers

#96
20100267637
2010-10-21

TREATMENT OF MELANOMA WITH ALPHA THYMOSIN PEPTIDES IN COMBINATION WITH A KINASE INHIBITOR

#97
20100221274
2010-09-02

METHOD OF ADMINISTERING A THYMOSIN ALPHA 1 PEPTIDE

#98
20100210540
2010-08-19

USE OF THE PEPTIDE COMBINATION THYMOSIN BETA 4 AND DELTA SLEEP INDUCING PEPTIDE AS A THERAPEUTIC AGENT

#99
20100204147
2010-08-12

Methods For Delivering Thymosin Beta 4, Analogues, Isoforms and Other Derivatives

#100
20100197595
2010-08-05

TREATMENT OF MELANOMA WITH ALPHA THYMOSIN PEPTIDES

#101
20100143300
2010-06-10

Hepatitis C therapies

#102
20100048474
2010-02-25

Method of treating or preventing tissue deterioration, injury or damage due to periodontal disease or disease of oral mucosa, and/or downregulating NF-kappabeta or supressing NF-kappabeta-mediated actions

#103
20100016211
2010-01-21

Treatment of Melanoma With Alpha Thymosin Peptides

#104
20100015090
2010-01-21

Combinations for HCV Treatment

#105
20100004174
2010-01-07

USE OF THYMOSIN ALPHA 1 FOR THE PREPARATION OF A MEDICAMENT FOR THE PREVENTION AND TREATMENT OF AUTOIMMUNE DISEASES

#106
20090275508
2009-11-05

Use of thymosin alpha 1, alone or in combination with PTX3 or ganciclovir, for the treatment of cytomegalovirus infection

#107
20090270594
2009-10-29

USE OF THYMOSIN ALPHA 1 FOR THE PREPARATION OF A MEDICAMENT FOR THE PREVENTION AND TREATMENT OF ALLERGIES

#108
20090270313
2009-10-29

Method of treatment for ischemic heart disease

#109
20090214507
2009-08-27

METHOD OF TREATING PREVENTING, INHIBITING OR REDUCING DAMAGE TO CARDIAC TISSUE

#110
20090186000
2009-07-23

Use of thymosin alpha 1 for preparing a medicament for the treatment of stage IV malignant melanoma

#111
20090169538
2009-07-02

Methods of Treating or Preventing Tissue Damage Caused by Increased Blood Flow

#112
20090169510
2009-07-02

NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION

#113
20090155260
2009-06-18

Use of thymosin alpha 1 for the treatment of immunological diseases

#114
20090148407
2009-06-11

Novel Macrocyclic Inhibitors of Hepatitis C Virus Replication

#115
20090131313
2009-05-21

LKKTET AND/OR LKKTNT PEPTIDE COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING TISSUE DETERIORATION, INJURY OR DAMAGE

#116
20090118196
2009-05-07

LKKTET and/or LKKTNT peptide compositions which are lyophilized or in a form capable of being lyophilized

#117
20090117187
2009-05-07

Method of treating or preventing tissue deterioration, injury or damage due to congestive heart failure

#118
20090110735
2009-04-30

Controlled release formulations

#119
20090023663
2009-01-22

Thymosin beta 4 compositions and methods

#120
20090018061
2009-01-15

Compositions comprising FGF-9 and betacellulin and methods for treating cardiac conditions

#121
20080300200
2008-12-04

Therapeutic furopyrimidines and thienopyrimidines

#122
20080300166
2008-12-04

Treatment of Melanoma with Alpha Thymosin Peptides

#123
20080287351
2008-11-20

NFκB transcriptional activity inhibitory agent and anti-inflammatory agent and a steroid action enhancing agent

#124
20080286267
2008-11-20

Methods for treating nervous system injury and disease

#125
20080274098
2008-11-06

Method of treating or preventing tissue deterioration, injury or damage due to a neuro-, muscular- or neuro-muscular-degenerative disease, or restore tissue adversely affected by said disease

#126
20080214456
2008-09-04

Lkktet and/or Lkktnt Peptide Compositions and Methods

#127
20080096817
2008-04-24

METHODS OF TREATING DISORDERS OF THE EYE AND SURROUNDING TISSUE WITH THYMOSIN BETA 4 (Tbeta4), ANALOGUES, ISOFORMS AND OTHER DERIVATIVES

#128
20080051348
2008-02-28

TREATMENT OF INFECTIONS AND OTHER DISORDERS

#129
20070292393
2007-12-20

Use of thymosin alpha 1 for preparing a medicament for the treatment of stage IV malignant melanoma

#130
20070292392
2007-12-20

USE OF THYMOSIN ALPHA 1 FOR PREPARING A MEDICAMENT FOR THE TREATMENT OF STAGE IV MALIGNANT MELANOMA

#131
20070218033
2007-09-20

Composition and method of treating hepatitis C

#132
20070196416
2007-08-23

Pharmaceutical compositions with enhanced stability

#133
20070191275
2007-08-16

Method of treating, preventing, inhibiting or reducing damage to cardiac tissue with thymosin beta 4 fragments

#134
20070129292
2007-06-07

Treatment of infections with alpha thymosin peptides

#135
20070111931
2007-05-17

Compositions and methods for promoting wound healing and tissue repair

#136
20070054842
2007-03-08

Macrocyclic inhibitors of hepatitis C virus replication

#137
20070036744
2007-02-15

Treatment or prevention of respiratory viral infections with alpha thymosin peptides

#138
20070021704
2007-01-25

Treatment of leg ulcers using placenta derived collagen biofabric

#139
20070015698
2007-01-18

Treatment of skin, and wound repair, with thymosin beta 4

#140
20070009469
2007-01-11

Treatment of skin, and wound repair, with thymosin beta 4

#141
20060263360
2006-11-23

Compositions and methods for delivering thymosin beta 4, analogues, isoforms and other derivatives

#142
20060258565
2006-11-16

Methods of inhibiting viral infection

#143
20060246057
2006-11-02

Treatment or prevention of damage due to radiation exposure

#144
20060234963
2006-10-19

Hepatitis C therapies

#145
20060204471
2006-09-14

Compositions and regime/regimen for treating the adverse signs of cutaneous skin aging

#146
20060166870
2006-07-27

Treatment of glioblastoma with thymosin-alpha 1

#147
20060165655
2006-07-27

Therapeutic furopyrimidines and thienopyrimidines

#148
20060089310
2006-04-27

Treatment of infections and other disorders

#149
20060052297
2006-03-09

Method of up-regulating tumor antigen expression using thymalfasin

#150
20060003942
2006-01-05

Combinations for HCV treatment

#151
20050239697
2005-10-27

Methods and compositions for the promotion of a hair growth utilizing actin binding peptides

#152
20050054845
2005-03-10

Thymosin augmentation of genetic immunization

#153
20050049191
2005-03-03

Method of administering a thymosin alpha 1 peptide

#154
20050020495
2005-01-27

Antiretroviral compositions comprising thymosin alpha peptides and protease inhibitors

#155
10488084
2015-06-16

Methods of healing or preventing inflammation, damage and other changes that occur prior to, during or immediately after a myocardial event with thymosin beta 4, analogues, isoforms and other derivatives